Abstract
Following a single-dose, open-label, pilot pharmacokinetic study in six subjects, the systemic pharmacokinetics and metabolic effects of dorzolamide after topical ocular administration were investigated in a double-blind, randomised, placebo-controlled study in 12 healthy volunteers. The subjects received a controlled diet on the 5 days before treatment initiation and throughout the study. For 14 days, a bilateral q.i.d. regimen of 3% dorzolamide, consisting of approximately 7.7 μg per day (21.3 μmol) dorzolamide hydrochloride, or placebo was given. Blood and urine electrolytes and acid-base profiles were measured 1 day prior to treatment and on days 1, 7 and 14 of treatment, and 24-h urine samples were collected daily.
Topically applied dorzolamide was slowly taken up in erythrocytes and eliminated with a half life of approximately 120 days. Compared to the pre-study values, no significant treatment effect was observed in either the daily profiles or the 14-day cumulative sodium, potassium and citrate excretions. Two other volunteers given acetazolamide (125 mg q.i.d.) and assessed with the identical set of observations demonstrated marked metabolic changes.
In spite of the prolonged and marked inhibition of carbonic anhydrase in red blood cells by dorzolamide, clinically significant metabolic and renal effects were not observed. The ocular tolerability profile was acceptable to all subjects.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Quigley HA (1993) Open-angle glaucoma. N Engl J Med 328:1097–1106
Wang RF, Serle JB, Podos SM, Sugrue MF (1990) The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys. Arch Ophthalmol 108:511–513
Sugrue MF, Waheed A, Sly WS, Baldwin JJ, Lumma WC, Sondey JM (1993) A study of the in vitro inhibition of human carbonic anhydrase isoenzymes I, II, and IV. Invest Ophthalmol Vis Sci 34 [Suppl]:930
Sugrue MF, Mallorga P, Schwam H, Baldwin JJ, Ponticello GS (1990) A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals. Curr Eye Res 9:607–615
Wilkerson M, Cyrlin M, Lippa EA, Esposito D, Deasy D, Panebianco D, Fazio R, Yablonski M, Shields MB (1993) Four-week safety nd efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 111:1343–1350
Lippa EA, Carlson LE, Ehinger B, Eriksson LO, Finnstrom K, Holmin C, Nilsson SE, Nyman K, Raitta C, Ringvold A (1991) Dose response and duration of action of dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 110:495–499
Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, Epstein DL, Shaw B, Holder DJ, Deasy DA, Wilensky JT (1990) MK-507 vs sezolamide: Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 98:308–312
Hofmann HM, Feicht B, Brunner-Ferber F, Lippa EA, Von Denffer H (1990) MK-507 (L-671,152): Lokale Verträglichkeit und Wirksamkeit eines neuen lokalen Karboanhydrasehemmers bei gesunden Probanden. Fortschr Ophthalmol 88:513–514
Lippa EA, Clineschmidt C, Tipping R, Strohmaier K, Dorzolamide Dose-Response Study Group (1993) Dorzolamide hydrochloride: six-week, dose-response study of an active, topical carbonic anhydrase inhibitor. Invest Ophthalmol Vis Sci 34 [Suppl]: 931
Frauenfelder FT, Mayer SM (1987) Systemic reactions to ophthalmic drug preparations. Med Toxicol 2:283–293
Salminen L (1990) Systemic absorption of topically applied ocular drugs in humans. J Ocul Pharmacol 6:243–249
Ponticello GS, Freedman MB, Habecker CN, et al (1987) Thienothiopyran-2-sulfonamides: a novel class of water-soluble carbonic anhydrase inhibitors. J Med Chem 30:591–597
Gothe PO, Nyman P (1972) Inactivation of human erythrocyte carbonic anhydrases by bromopyruvate. FEBS Lett 21:159–164
Matuszewski BK, Constanzer ML, Woolf EJ, Au T, Haddix H (1994) Determination of MK-507, a novel topically effective carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography. J Chromatogr 653:77–85
Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures. J Pharmacokinet Biopharm 15:185–201
Zar JH (1984) Biostatistical analysis. Prentice-Hall, Englewood Cliffs, New Jersey, pp 171–176
Buclin T, Biollaz J, Lippa EA, Brunner-Ferber F, van Melle G, Munafo A, Clineschmidt C, Schelling JL (1991) Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clin Pharmacol Ther 49:665–673
Maren TH (1967) Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 7:595–781
Notstrand B, Vaara I, Kannan KK (1975) Structural relationship of human erythrocyte carbonic anhydrase B and C. Isoenzymes 1:575–599
Sanyal G (1984) Comparative carbon dioxide hydration kinetics and inhibition of carbonic anhydrase isozymes in vertebrates. Ann NY Acad Sci 429:165–178
Maren TH (1963) The relation between enzyme inhibition and physiological response in the carbonic anhydrase system. J Pharmacol Exp Ther 139:140–153
Lucci MS, Tinker JP, Weiner IM, DuBose TD (1983) Function of proximal tubule carbonic anhydrase defined by selective inhibition. Am J Physiol 245:F443-F449
Preisig PA, Toto RD, Alpern RJ (1987) Carbonic anhydrase inhibitors. Renal Physiol Biochem 10:136–159
Cowan RA, Hartnell GG, Lowdell CP, McLean Baird I, Leak AM (1984) Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function. BMJ 289:347–349
Reeder J, Wallace MR (1971) The effect of carbonic anhydrase inhibitors on urinary calcium and citrate. Trans Ophthalmol NZ 31:51–52
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Biollaz, J., Munafo, A., Buclin, T. et al. Whole-blood pharmacokinetics and metabolic effects of the topical carbonic anhydrase inhibitor dorzolamide. Eur J Clin Pharmacol 47, 453–460 (1995). https://doi.org/10.1007/BF00196861
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00196861